State Insurance Panels Overturn Many Health Coverage Denials, Improving Access

A case in North Carolina highlights the importance of state-run external review panels in overturning insurance denials for medically necessary treatments under the Affordable Care Act. Paxton Pope, a 13-year-old with a rare genetic condition resulting in frequent seizures, was initially denied coverage twice for a nearly $800,000/year drug that his doctor believed would reduce his seizures. The family accessed a provision in the ACA allowing an independent state insurance department panel to review the denial. The North Carolina Department of Insurance helped overturn the insurer's refusal, enabling access to the drug, which significantly reduced Paxton's seizures and improved his quality of life. State insurance departments play a pivotal role in assisting policyholders in appealing denied claims beyond insurers' internal processes by facilitating external reviews that often involve independent medical experts. Such panels issue binding decisions as mandated by federal law when a doctor certifies a treatment as medically necessary despite insurer denials. These resources remain underutilized due to limited public awareness. Statistical data indicates that millions of insured Americans face claim denials annually, with surveys revealing a majority encountering problems using health insurance. Despite these challenges, patients often abandon appeals prematurely because they are unaware of external review options and state-level assistance. The North Carolina program handling these appeals, Smart NC, has achieved an overturn rate of about 53%, consistent with similar programs in states like Kansas, California, Colorado, and South Carolina, where roughly 40-55% of external reviews result in overturned denials. Lower overturn rates exist in states such as Washington and West Virginia. These figures underscore variability in success rates but also affirm the value of further review. Insurance commissioners emphasize regulatory oversight responsibilities including enforcement of insurance laws, ensuring insurer fairness, and assistance with issues like surprise medical bills, prior authorizations, and fraud detection. These regulatory frameworks aim to support consumer protection and industry compliance. Advocates acknowledge that navigating insurance appeals and external reviews can be taxing for patients and families, especially amidst serious health issues. Complexity, wait times, and administrative burden can impede timely access to necessary care, highlighting an area for systemic improvement. In Paxton's case, the external review process took approximately five months from initial prescription request to approval, illustrating both the potential benefits and time constraints of current appeal mechanisms. The family encourages greater awareness to empower others facing insurance denials to pursue external reviews via state insurance departments. This case and its broader context emphasize the critical intersection of insurance regulation, patient advocacy, and healthcare accessibility. They reflect ongoing challenges in securing coverage for high-cost or off-label treatments through insurer appeals followed by external oversight. State agency involvement helps mitigate insurer denials, facilitating better alignment between clinical necessity and payer decisions.